世界の加齢性黄斑変性症（AMD）市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Wet Age Related Macular Degeneration (AMD) Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z6010 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、加齢性黄斑変性症（AMD）のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（湿性加齢性黄斑変性症（湿性AMD）、乾性加齢性黄斑変性症（乾性AMD））、用途別市場規模（75歳以上、60歳以上、40歳以上）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・加齢性黄斑変性症（AMD）の市場動向 ・企業の競争状況、市場シェア ・加齢性黄斑変性症（AMD）の種類別市場規模（湿性加齢性黄斑変性症（湿性AMD）、乾性加齢性黄斑変性症（乾性AMD）） ・加齢性黄斑変性症（AMD）の用途別市場規模（75歳以上、60歳以上、40歳以上） ・加齢性黄斑変性症（AMD）の北米市場規模2016-2027（アメリカ、カナダ） ・加齢性黄斑変性症（AMD）のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・加齢性黄斑変性症（AMD）のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・加齢性黄斑変性症（AMD）の中南米市場規模2016-2027（メキシコ、ブラジル） ・加齢性黄斑変性症（AMD）の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis International (Switzerland)、Bayer (Germany)、Acucela (US)、Neurotech Pharmaceuticals (US)、Ophthotech (US)、GlaxoSmithKline (US)、Alimera Sciences (US)、StemCell (Canada)、F. Hoffmann-La Roche (Switzerland)、Regeneron Pharmaceutical (US)、Allergan (Ireland)、Adverum Biotechnologies (US)、Gilead Sciences (US)） ・結論

Increased disease burden due to rising geriatric population is one of the major factors driving the growth of the global age-related macular degeneration (AMD) market. This market is expected to surpass a valuation of USD 2,200 Mn by the end of 2023. AMD remains a major cause of central visual loss, effecting close to 10% of people older than 65 years and over 25% of people older than 75 years globally.
Increased awareness among people about the condition has influenced the AMD treatment global demand. At the same time, the arrival of off-patent blockbuster drugs is reflecting favorably on the market particularly in third-world countries. This has allowed small-scale drug manufactures to penetrate untapped markets.

Market Analysis and Insights: Global Wet Age Related Macular Degeneration (AMD) Market
The global Wet Age Related Macular Degeneration (AMD) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Wet Age Related Macular Degeneration (AMD) market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Wet Age Related Macular Degeneration (AMD) market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Wet Age Related Macular Degeneration (AMD) market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Wet Age Related Macular Degeneration (AMD) market.

Global Wet Age Related Macular Degeneration (AMD) Scope and Market Size
Wet Age Related Macular Degeneration (AMD) market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Wet Age Related Macular Degeneration (AMD) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Age in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Wet Age-Related Macular Degeneration (Wet AMD)
Dry Age-Related Macular Degeneration (Dry AMD)

Segment by Age
Above 75 Years
Above 60 Years
Above 40 Years

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis International (Switzerland)
Bayer (Germany)
Acucela (US)
Neurotech Pharmaceuticals (US)
Ophthotech (US)
GlaxoSmithKline (US)
Alimera Sciences (US)
StemCell (Canada)
F. Hoffmann-La Roche (Switzerland)
Neurotech Pharmaceuticals (US)
Ophthotech (US)

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Wet Age Related Macular Degeneration (AMD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Wet Age-Related Macular Degeneration (Wet AMD)
1.2.3 Dry Age-Related Macular Degeneration (Dry AMD)
1.3 Market by Application
1.3.1 Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2016 VS 2021 VS 2027
1.3.2 Above 75 Years
1.3.3 Above 60 Years
1.3.4 Above 40 Years
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Wet Age Related Macular Degeneration (AMD) Market Perspective (2016-2027)
2.2 Wet Age Related Macular Degeneration (AMD) Growth Trends by Regions
2.2.1 Wet Age Related Macular Degeneration (AMD) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Wet Age Related Macular Degeneration (AMD) Historic Market Share by Regions (2016-2021)
2.2.3 Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Regions (2022-2027)
2.3 Wet Age Related Macular Degeneration (AMD) Industry Dynamic
2.3.1 Wet Age Related Macular Degeneration (AMD) Market Trends
2.3.2 Wet Age Related Macular Degeneration (AMD) Market Drivers
2.3.3 Wet Age Related Macular Degeneration (AMD) Market Challenges
2.3.4 Wet Age Related Macular Degeneration (AMD) Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Revenue
3.1.1 Global Top Wet Age Related Macular Degeneration (AMD) Players by Revenue (2016-2021)
3.1.2 Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Players (2016-2021)
3.2 Global Wet Age Related Macular Degeneration (AMD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Wet Age Related Macular Degeneration (AMD) Revenue
3.4 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio
3.4.1 Global Wet Age Related Macular Degeneration (AMD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Wet Age Related Macular Degeneration (AMD) Revenue in 2020
3.5 Wet Age Related Macular Degeneration (AMD) Key Players Head office and Area Served
3.6 Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
3.7 Date of Enter into Wet Age Related Macular Degeneration (AMD) Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Wet Age Related Macular Degeneration (AMD) Breakdown Data by Type
4.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Type (2016-2021)
4.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Type (2022-2027)

5 Wet Age Related Macular Degeneration (AMD) Breakdown Data by Age
5.1 Global Wet Age Related Macular Degeneration (AMD) Historic Market Size by Age (2016-2021)
5.2 Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Age (2022-2027)

6 North America
6.1 North America Wet Age Related Macular Degeneration (AMD) Market Size (2016-2027)
6.2 North America Wet Age Related Macular Degeneration (AMD) Market Size by Type
6.2.1 North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021)
6.2.2 North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027)
6.2.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2027)
6.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Age
6.3.1 North America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021)
6.3.2 North America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027)
6.3.3 North America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2027)
6.4 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country
6.4.1 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021)
6.4.2 North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size (2016-2027)
7.2 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type
7.2.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021)
7.2.2 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027)
7.2.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2027)
7.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Age
7.3.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021)
7.3.2 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027)
7.3.3 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2027)
7.4 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country
7.4.1 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021)
7.4.2 Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size (2016-2027)
8.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Type
8.2.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2027)
8.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Age
8.3.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021)
8.3.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027)
8.3.3 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2027)
8.4 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region
8.4.1 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Wet Age Related Macular Degeneration (AMD) Market Size (2016-2027)
9.2 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Type
9.2.1 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021)
9.2.2 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027)
9.2.3 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2027)
9.3 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Age
9.3.1 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021)
9.3.2 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027)
9.3.3 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2027)
9.4 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country
9.4.1 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021)
9.4.2 Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size (2016-2027)
10.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Type
10.2.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2027)
10.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Age
10.3.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021)
10.3.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027)
10.3.3 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2027)
10.4 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country
10.4.1 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis International (Switzerland)
11.1.1 Novartis International (Switzerland) Company Details
11.1.2 Novartis International (Switzerland) Business Overview
11.1.3 Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
11.1.4 Novartis International (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.1.5 Novartis International (Switzerland) Recent Development
11.2 Bayer (Germany)
11.2.1 Bayer (Germany) Company Details
11.2.2 Bayer (Germany) Business Overview
11.2.3 Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Introduction
11.2.4 Bayer (Germany) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.2.5 Bayer (Germany) Recent Development
11.3 Acucela (US)
11.3.1 Acucela (US) Company Details
11.3.2 Acucela (US) Business Overview
11.3.3 Acucela (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.3.4 Acucela (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.3.5 Acucela (US) Recent Development
11.4 Neurotech Pharmaceuticals (US)
11.4.1 Neurotech Pharmaceuticals (US) Company Details
11.4.2 Neurotech Pharmaceuticals (US) Business Overview
11.4.3 Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.4.4 Neurotech Pharmaceuticals (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.4.5 Neurotech Pharmaceuticals (US) Recent Development
11.5 Ophthotech (US)
11.5.1 Ophthotech (US) Company Details
11.5.2 Ophthotech (US) Business Overview
11.5.3 Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.5.4 Ophthotech (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.5.5 Ophthotech (US) Recent Development
11.6 GlaxoSmithKline (US)
11.6.1 GlaxoSmithKline (US) Company Details
11.6.2 GlaxoSmithKline (US) Business Overview
11.6.3 GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.6.4 GlaxoSmithKline (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.6.5 GlaxoSmithKline (US) Recent Development
11.7 Alimera Sciences (US)
11.7.1 Alimera Sciences (US) Company Details
11.7.2 Alimera Sciences (US) Business Overview
11.7.3 Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.7.4 Alimera Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.7.5 Alimera Sciences (US) Recent Development
11.8 StemCell (Canada)
11.8.1 StemCell (Canada) Company Details
11.8.2 StemCell (Canada) Business Overview
11.8.3 StemCell (Canada) Wet Age Related Macular Degeneration (AMD) Introduction
11.8.4 StemCell (Canada) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.8.5 StemCell (Canada) Recent Development
11.9 F. Hoffmann-La Roche (Switzerland)
11.9.1 F. Hoffmann-La Roche (Switzerland) Company Details
11.9.2 F. Hoffmann-La Roche (Switzerland) Business Overview
11.9.3 F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Introduction
11.9.4 F. Hoffmann-La Roche (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.9.5 F. Hoffmann-La Roche (Switzerland) Recent Development
11.10 Regeneron Pharmaceutical (US)
11.10.1 Regeneron Pharmaceutical (US) Company Details
11.10.2 Regeneron Pharmaceutical (US) Business Overview
11.10.3 Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.10.4 Regeneron Pharmaceutical (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.10.5 Regeneron Pharmaceutical (US) Recent Development
11.11 Allergan (Ireland)
11.11.1 Allergan (Ireland) Company Details
11.11.2 Allergan (Ireland) Business Overview
11.11.3 Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Introduction
11.11.4 Allergan (Ireland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.11.5 Allergan (Ireland) Recent Development
11.12 Adverum Biotechnologies (US)
11.12.1 Adverum Biotechnologies (US) Company Details
11.12.2 Adverum Biotechnologies (US) Business Overview
11.12.3 Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.12.4 Adverum Biotechnologies (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.12.5 Adverum Biotechnologies (US) Recent Development
11.13 Gilead Sciences (US)
11.13.1 Gilead Sciences (US) Company Details
11.13.2 Gilead Sciences (US) Business Overview
11.13.3 Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Introduction
11.13.4 Gilead Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
11.13.5 Gilead Sciences (US) Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Wet Age Related Macular Degeneration (AMD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Wet Age-Related Macular Degeneration (Wet AMD)
Table 3. Key Players of Dry Age-Related Macular Degeneration (Dry AMD)
Table 4. Global Wet Age Related Macular Degeneration (AMD) Market Size Growth by Age (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Wet Age Related Macular Degeneration (AMD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Wet Age Related Macular Degeneration (AMD) Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions (2016-2021)
Table 8. Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions (2022-2027)
Table 10. Wet Age Related Macular Degeneration (AMD) Market Trends
Table 11. Wet Age Related Macular Degeneration (AMD) Market Drivers
Table 12. Wet Age Related Macular Degeneration (AMD) Market Challenges
Table 13. Wet Age Related Macular Degeneration (AMD) Market Restraints
Table 14. Global Wet Age Related Macular Degeneration (AMD) Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Wet Age Related Macular Degeneration (AMD) Market Share by Players (2016-2021)
Table 16. Global Top Wet Age Related Macular Degeneration (AMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Wet Age Related Macular Degeneration (AMD) as of 2020)
Table 17. Ranking of Global Top Wet Age Related Macular Degeneration (AMD) Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Wet Age Related Macular Degeneration (AMD) Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Wet Age Related Macular Degeneration (AMD) Product Solution and Service
Table 21. Date of Enter into Wet Age Related Macular Degeneration (AMD) Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type (2016-2021)
Table 25. Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Wet Age Related Macular Degeneration (AMD) Market Size Share by Age (2016-2021) & (US$ Million)
Table 28. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Age (2016-2021)
Table 29. Global Wet Age Related Macular Degeneration (AMD) Forecasted Market Size by Age (2022-2027) (US$ Million)
Table 30. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Age (2022-2027) & (US$ Million)
Table 31. North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021) (US$ Million)
Table 34. North America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027) & (US$ Million)
Table 35. North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021) (US$ Million)
Table 40. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027) & (US$ Million)
Table 41. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021) (US$ Million)
Table 46. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021) (US$ Million)
Table 52. Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027) & (US$ Million)
Table 53. Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Age (2016-2021) (US$ Million)
Table 58. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Age (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size by Country (2022-2027) & (US$ Million)
Table 61. Novartis International (Switzerland) Company Details
Table 62. Novartis International (Switzerland) Business Overview
Table 63. Novartis International (Switzerland) Wet Age Related Macular Degeneration (AMD) Product
Table 64. Novartis International (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 65. Novartis International (Switzerland) Recent Development
Table 66. Bayer (Germany) Company Details
Table 67. Bayer (Germany) Business Overview
Table 68. Bayer (Germany) Wet Age Related Macular Degeneration (AMD) Product
Table 69. Bayer (Germany) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 70. Bayer (Germany) Recent Development
Table 71. Acucela (US) Company Details
Table 72. Acucela (US) Business Overview
Table 73. Acucela (US) Wet Age Related Macular Degeneration (AMD) Product
Table 74. Acucela (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 75. Acucela (US) Recent Development
Table 76. Neurotech Pharmaceuticals (US) Company Details
Table 77. Neurotech Pharmaceuticals (US) Business Overview
Table 78. Neurotech Pharmaceuticals (US) Wet Age Related Macular Degeneration (AMD) Product
Table 79. Neurotech Pharmaceuticals (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 80. Neurotech Pharmaceuticals (US) Recent Development
Table 81. Ophthotech (US) Company Details
Table 82. Ophthotech (US) Business Overview
Table 83. Ophthotech (US) Wet Age Related Macular Degeneration (AMD) Product
Table 84. Ophthotech (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 85. Ophthotech (US) Recent Development
Table 86. GlaxoSmithKline (US) Company Details
Table 87. GlaxoSmithKline (US) Business Overview
Table 88. GlaxoSmithKline (US) Wet Age Related Macular Degeneration (AMD) Product
Table 89. GlaxoSmithKline (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 90. GlaxoSmithKline (US) Recent Development
Table 91. Alimera Sciences (US) Company Details
Table 92. Alimera Sciences (US) Business Overview
Table 93. Alimera Sciences (US) Wet Age Related Macular Degeneration (AMD) Product
Table 94. Alimera Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 95. Alimera Sciences (US) Recent Development
Table 96. StemCell (Canada) Company Details
Table 97. StemCell (Canada) Business Overview
Table 98. StemCell (Canada) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 99. StemCell (Canada) Recent Development
Table 100. F. Hoffmann-La Roche (Switzerland) Company Details
Table 101. F. Hoffmann-La Roche (Switzerland) Business Overview
Table 102. F. Hoffmann-La Roche (Switzerland) Wet Age Related Macular Degeneration (AMD) Product
Table 103. F. Hoffmann-La Roche (Switzerland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 104. F. Hoffmann-La Roche (Switzerland) Recent Development
Table 105. Regeneron Pharmaceutical (US) Company Details
Table 106. Regeneron Pharmaceutical (US) Business Overview
Table 107. Regeneron Pharmaceutical (US) Wet Age Related Macular Degeneration (AMD) Product
Table 108. Regeneron Pharmaceutical (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 109. Regeneron Pharmaceutical (US) Recent Development
Table 110. Allergan (Ireland) Company Details
Table 111. Allergan (Ireland) Business Overview
Table 112. Allergan (Ireland) Wet Age Related Macular Degeneration (AMD) Product
Table 113. Allergan (Ireland) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 114. Allergan (Ireland) Recent Development
Table 115. Adverum Biotechnologies (US) Company Details
Table 116. Adverum Biotechnologies (US) Business Overview
Table 117. Adverum Biotechnologies (US) Wet Age Related Macular Degeneration (AMD) Product
Table 118. Adverum Biotechnologies (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 119. Adverum Biotechnologies (US) Recent Development
Table 120. Gilead Sciences (US) Company Details
Table 121. Gilead Sciences (US) Business Overview
Table 122. Gilead Sciences (US) Wet Age Related Macular Degeneration (AMD) Product
Table 123. Gilead Sciences (US) Revenue in Wet Age Related Macular Degeneration (AMD) Business (2016-2021) & (US$ Million)
Table 124. Gilead Sciences (US) Recent Development
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Wet Age Related Macular Degeneration (AMD) Market Share by Type: 2020 VS 2027
Figure 2. Wet Age-Related Macular Degeneration (Wet AMD) Features
Figure 3. Dry Age-Related Macular Degeneration (Dry AMD) Features
Figure 4. Global Wet Age Related Macular Degeneration (AMD) Market Share by Age: 2020 VS 2027
Figure 5. Above 75 Years Case Studies
Figure 6. Above 60 Years Case Studies
Figure 7. Above 40 Years Case Studies
Figure 8. Wet Age Related Macular Degeneration (AMD) Report Years Considered
Figure 9. Global Wet Age Related Macular Degeneration (AMD) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Wet Age Related Macular Degeneration (AMD) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions: 2020 VS 2027
Figure 12. Global Wet Age Related Macular Degeneration (AMD) Market Share by Regions (2022-2027)
Figure 13. Global Wet Age Related Macular Degeneration (AMD) Market Share by Players in 2020
Figure 14. Global Top Wet Age Related Macular Degeneration (AMD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Wet Age Related Macular Degeneration (AMD) as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Wet Age Related Macular Degeneration (AMD) Revenue in 2020
Figure 16. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type (2016-2021)
Figure 17. Global Wet Age Related Macular Degeneration (AMD) Revenue Market Share by Type (2022-2027)
Figure 18. North America Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Wet Age Related Macular Degeneration (AMD) Market Share by Type (2016-2027)
Figure 20. North America Wet Age Related Macular Degeneration (AMD) Market Share by Age (2016-2027)
Figure 21. North America Wet Age Related Macular Degeneration (AMD) Market Share by Country (2016-2027)
Figure 22. United States Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Wet Age Related Macular Degeneration (AMD) Market Share by Type (2016-2027)
Figure 26. Europe Wet Age Related Macular Degeneration (AMD) Market Share by Age (2016-2027)
Figure 27. Europe Wet Age Related Macular Degeneration (AMD) Market Share by Country (2016-2027)
Figure 28. Germany Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Share by Age (2016-2027)
Figure 37. Asia-Pacific Wet Age Related Macular Degeneration (AMD) Market Share by Region (2016-2027)
Figure 38. China Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Wet Age Related Macular Degeneration (AMD) Market Share by Type (2016-2027)
Figure 46. Latin America Wet Age Related Macular Degeneration (AMD) Market Share by Age (2016-2027)
Figure 47. Latin America Wet Age Related Macular Degeneration (AMD) Market Share by Country (2016-2027)
Figure 48. Mexico Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Share by Age (2016-2027)
Figure 53. Middle East & Africa Wet Age Related Macular Degeneration (AMD) Market Share by Country (2016-2027)
Figure 54. Turkey Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Wet Age Related Macular Degeneration (AMD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Novartis International (Switzerland) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 58. Bayer (Germany) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 59. Acucela (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 60. Neurotech Pharmaceuticals (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 61. Ophthotech (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 62. GlaxoSmithKline (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 63. Alimera Sciences (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 64. StemCell (Canada) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 65. F. Hoffmann-La Roche (Switzerland) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 66. Regeneron Pharmaceutical (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 67. Allergan (Ireland) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 68. Adverum Biotechnologies (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 69. Gilead Sciences (US) Revenue Growth Rate in Wet Age Related Macular Degeneration (AMD) Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---